title: Role of enterocytes in dyslipidemia of insulin-resistant states.
abstract: The increase in cardiovascular morbidity and mortality associated to insulin resistance (IR) states (obesity, metabolic syndrome, type 2 diabetes) represents a major public health problem. In IR, dyslipidemia typically include hypertriglyceridemia, low high density lipoprotein cholesterol, increased small and dense low density lipoprotein particles, and post-prandial hyperlipidemia, which play a direct or indirect role in the mechanisms of atherosclerosis. Dyslipidemia is mainly due to accumulation of circulating triglyceride-rich lipoproteins from the liver and bowel. The bowel has traditionally been seen as a passive organ, but current evidence confirms that it is an active organ subject to regulation by free fatty acids, insulin, incretins, and inflammation. Two new concepts have emerged: intestinal IR and overproduction of chylomicrons in hyperinsulinemic/IR states. A better understanding of intestinal IR may make the enterocyte a therapeutic target.
authors.affiliation: Servicio de Endocrinología, Metabolismo y Medicina Nuclear, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. juanpnog@yahoo.com
authors.forename: Juan Patricio
authors.initials: JP
authors.lastname: Nogueira
authors.forename: Fernando Daniel
authors.initials: FD
authors.lastname: Brites
mesh_terms: D000818:Animals; D050171:Dyslipidemias / Q000209:etiology*; D020895:Enterocytes / Q000502:physiology*; D006801:Humans; D007333:Insulin Resistance; D007413:Intestinal Mucosa / Q000378:metabolism; D008074:Lipoproteins / Q000378:metabolism; D014280:Triglycerides / Q000378:metabolism
chemical_list: D008074:Lipoproteins; D014280:Triglycerides